
Please try another search
Symbol | Exchange | Currency | ||
---|---|---|---|---|
AZN | London | GBP | Real-time | |
3LAZ | London | GBP | Real-time | |
3SAZ | London | GBP | Real-time | |
AZNl | BATS Europe | GBP | Delayed | |
AZNs | BATS Europe | SEK | Delayed | |
AZN | NASDAQ | USD | Real-time | |
AZNCF | OTC Markets | USD | Delayed | |
AZNN | BIVA | MXN | Delayed | |
AZNN | Mexico | MXN | Delayed | |
AZN | Stockholm | SEK | Real-time | |
AZNPy | Frankfurt | EUR | Delayed | |
AZN | Frankfurt | EUR | Delayed | |
AZN | TradeGate | EUR | Delayed | |
AZN | Xetra | EUR | Delayed | |
AZN | Buenos Aires | ARS | Delayed | |
AZNA | Vienna | EUR | Delayed |
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, andcommercialization of prescription medicines. The company’s marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Andexxa/Ondexxya, Atacand, Atacand HCT, Atacand Plus, Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, Xigduo/Xigduo, and Zestril XR for cardiovascular, renal, and metabolism diseases; Accolate, Accoleit, Vanticon, Bevespi Aerosphere, Breztri Aerosphere, Bricanyl Respules and Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Rhinocort, Saphnelo, Symbicort, and Tezspire for respiratory and immunology; and Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. Its marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; and Personalis, Inc, as well as research collaboration with Sernova Corp. to evaluate novel potential therapeutic cell applications; and collaboration with Cholesgen (Shanghai) Co.Ltd. to advance research and development in hypercholesterolemia and related metabolic diseases, as well as a collaboration with BioCity Biopharma to evaluate a monoclonal antibody for the treatment of advanced hepatocellular carcinoma and a collaboration agreement with Cellectis. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Name | Age | Since | Title |
---|---|---|---|
Pascal Soriot | 62 | 2012 | CEO & Executive Director |
Philip Arthur John Broadley | 62 | 2017 | Senior Independent Non-Executive Director |
Marcus Wallenberg | 67 | 1999 | Non-Executive Director |
Deborah DiSanzo Eldracher | 63 | 2017 | Independent Non-Executive Director |
Shu Kam Mok | 61 | 2019 | Independent Non-Executive Director |
Nazneen Rahman | 55 | 2017 | Independent Non-Executive Director |
Rain Henderson | - | - | Member of External Sustainability Advisory Board |
Diana Layfield | 51 | 2020 | Independent Non-Executive Director |
Sherilyn S. D. McCoy | 64 | 2017 | Independent Non-Executive Director |
Pankaj Bhatia | - | - | Member of External Sustainability Advisory Board |
Michel Demare | 67 | 2019 | Independent Chairman |
Polly Courtice | 71 | - | Member of External Sustainability Advisory Board |
Louise Nicholls | - | - | Member of External Sustainability Advisory Board |
Euan A. Ashley | 51 | 2020 | Independent Non-Executive Director |
Andreas Rummelt | 67 | 2021 | Independent Non-Executive Director |
Anna Olive Magdelene Manz | 50 | 2023 | Non-Executive Director |
Jeffrey Pott | - | 2009 | CHRO, Chief Compliance Officer, General Counsel & Member of External Sustainability Advisory Board |
Pam P. Cheng | 52 | 2015 | EVP of Global opt. & IT, Chief Sust. Officer and Member of External Sust.Adv. Board |
Menelas Pangalos | 56 | 2013 | EVP of BioPharmaceuticals R&D and Member of External Sustainability Advisory Board |
Aradhana Sarin | 48 | 2021 | CFO & Executive Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review